AAM wants US to cut China tariff on APIs

Tariffs on active pharmaceutical ingredients (APIs) imported into the US from China must be cut from a package of measures proposed by the US Trade Representative (USTR), to avoid drug shortages, higher costs and firms dropping out of the generics market, according to the US Association for Accessible Medicines (AAM).